Moderna projects improved 2025 financials, outlines 2026 growth, and details multiple pipeline catalysts

summarizeSummary

Moderna provided preliminary positive financial results for 2025, reiterated 2026 revenue growth targets with further cost reductions, and highlighted numerous key pipeline milestones expected in 2026.

check_boxKey Events

• Preliminary 2025 Financials Exceed Expectations

  Moderna reported approximately $1.9 billion in unaudited revenue for fiscal year 2025, exceeding the midpoint of its previously communicated range. GAAP operating expenses for 2025 are expected to be $5.0 - $5.2 billion, an improvement of $200 million from prior guidance.

• Positive 2026 Financial Outlook and Cost Reductions

  The company reiterated its target of up to 10% revenue growth in 2026 and projected further GAAP operating expense reductions to approximately $4.9 billion. Moderna aims for cash breakeven by 2028.

• Strong Cash Position and New Financing

  Moderna ended 2025 with approximately $8.1 billion in unaudited cash, cash equivalents, and investments, which includes a $0.6 billion drawdown from a recently closed $1.5 billion five-year term loan facility.

• Multiple Key Pipeline Catalysts Expected in 2026

  The company anticipates potential first approvals for its seasonal flu and flu/COVID combination vaccines in 2026. Additionally, pivotal trial data readouts are expected for its RSV vaccine, oncology candidates (melanoma), and rare disease therapeutics (Propionic Acidemia).

auto_awesomeAnalysis

Moderna's comprehensive update at the J.P. Morgan Healthcare Conference signals a strong operational and strategic outlook. The company exceeded its 2025 revenue midpoint and significantly improved operating expense guidance, demonstrating effective cost management. The reiteration of 2026 revenue growth and further expense reductions, alongside a target for cash breakeven by 2028, provides a clear path to profitability. Crucially, the extensive list of potential product approvals and pivotal trial data readouts across its seasonal vaccine, oncology, and rare disease portfolios in 2026 indicates a year rich with catalysts that could drive future growth and market expansion. The robust cash position, supported by a new term loan and external funding for a vaccine candidate, further strengthens the company's financial flexibility to execute on its pipeline.